Guided Therapeutics (GTHP) FCF Margin (2011 - 2025)
Guided Therapeutics (GTHP) posted FCF Margin of 49.32% for Q4 2025, up 89.32% sequentially from 461.67% in Q3 2025, and up 3315068.0% YoY from N/an in Q4 2024.
Guided Therapeutics (GTHP) FCF Margin (2011 - 2025) Analysis & Trends
Guided Therapeutics has reported FCF Margin for 15 years, with the latest figure at 49.32% in Q4 2025.
- Quarterly FCF Margin rose 3315068.0% year-over-year to 49.32% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 139.24% (up 1584647.0% YoY) and the FY2025 annual result came in at 139.5%, up 1584621.0% from the prior year.
- FCF Margin improved to 49.32% in Q4 2025 per GTHP's latest filing, from 461.67% in the prior quarter.
- Over five years, FCF Margin peaked at 213.33% in Q4 2021 and troughed at 34800.0% in Q2 2021.
- A 5-year average of 7834.01% and a median of 1967.42% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin slumped 3215000 bps in 2024, then jumped 3315068 bps in 2025.
- Over 5 years, FCF Margin stood at 213.33% in 2021, then plunged by 9616 bps to 20300.0% in 2022, then soared by 95 bps to 1050.0% in 2023, then sank by 3062 bps to 33200.0% in 2024, then soared by 100 bps to 49.32% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 49.32%, 461.67%, and 144.44% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.61 Bn | 194.01 Bn | 7.27 Bn | 15.81% |
| 2 | Stryker | 127.81 Bn | 124.34 Bn | 4.50 Bn | 16.07% |
| 3 | Medtronic | 119.04 Bn | 109.82 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 73.68 Bn | 73.14 Bn | 3.85 Bn | 23.50% |
| 5 | Edwards Lifesciences | 51.96 Bn | 47.71 Bn | 1.35 Bn | 33.60% |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 14.10% |
| 7 | GE HealthCare Technologies | 33.83 Bn | 31.72 Bn | 2.18 Bn | 1.28% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 5.32% |
| 9 | Steris | 23.06 Bn | 22.58 Bn | 684.20 Mn | 18.73% |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.32% |
| Sep 30, 2025 | -461.67% |
| Jun 30, 2025 | -144.44% |
| Dec 31, 2024 | -33,200.00% |
| Mar 31, 2024 | -1,666.67% |
| Dec 31, 2023 | -1,050.00% |
| Jun 30, 2023 | -995.45% |
| Mar 31, 2023 | -2,268.18% |
| Sep 30, 2022 | -20,300.00% |
| Jun 30, 2022 | -7,320.00% |
| Mar 31, 2022 | -3,860.00% |
| Dec 31, 2021 | 213.33% |
| Sep 30, 2021 | -3,773.68% |
| Jun 30, 2021 | -34,800.00% |
| Dec 31, 2020 | -1,324.00% |
| Sep 30, 2020 | -764.94% |
| Dec 31, 2019 | -1,268.75% |
| Sep 30, 2019 | -22,800.00% |
| Jun 30, 2019 | -18,800.00% |
| Mar 31, 2019 | -1,033.33% |